Switching from Reference to Biosimilar Adalimumab for Patients with Various Inflammatory Conditions

Details

Files

Project Line:

Reference List

Project Sub Line:

Summary of Abstracts

Project Number:

RB1552-000

Question

What is the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with rheumatoid arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, or uveitis?
What is the clinical effectiveness of switching from reference to biosimilar adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis?

Key Message

Ten randomized controlled trials and 4 non-randomized studies were identified regarding the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with rheumatoid arthritis, Crohn disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, or psoriatic arthritis. No evidence was identified regarding the clinical effectiveness of switching from reference to biosimilar adalimumab in adult or pediatric patients with uveitis or ankylosing spondylitis and in pediatric patients with polyarticular juvenile idiopathic arthritis.

Files

Switching from Reference to Biosimilar Adalimumab for Patients with Various Inflammatory Conditions Rapid Response February 10, 2021 View PDF

Last Updated : February 16, 2021